$BCRX
BIOCRYST PHARMACEUTICALS INC

2021 Q1 Form 10-K Financial Statement

#000117184321001411 Filed on March 01, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q4 2019 Q4
Revenue $19.06M $4.016M $39.73M
YoY Change 295.17% -89.89% 1355.66%
Cost Of Revenue $5.923M $80.00K $2.570M
YoY Change -96.89% 3571.43%
Gross Profit $13.14M $3.940M $37.15M
YoY Change 172.36% -89.39% 1296.62%
Gross Profit Margin 68.92% 98.11% 93.52%
Selling, General & Admin $22.11M $20.99M $10.49M
YoY Change 39.39% 100.1% 150.36%
% of Gross Profit 168.35% 532.74% 28.24%
Research & Development $42.44M $35.35M $26.77M
YoY Change 42.08% 32.05% 14.26%
% of Gross Profit 323.04% 897.21% 72.06%
Depreciation & Amortization $178.0K $180.0K $180.0K
YoY Change -18.35% 0.0% -10.0%
% of Gross Profit 1.36% 4.57% 0.48%
Operating Expenses $64.55M $56.34M $37.26M
YoY Change 41.15% 51.21% 34.9%
Operating Profit -$51.38M -$52.40M -$110.0K
YoY Change 25.38% 47536.36% -99.56%
Interest Expense $12.90M -$6.080M -$2.510M
YoY Change 323.5% 142.23% 15.67%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$64.28M -$60.49M -$2.620M
YoY Change 70.97% 2208.78% -90.45%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$64.28M -$60.49M -$2.622M
YoY Change 70.97% 2207.13% -90.44%
Net Earnings / Revenue -337.29% -1506.3% -6.6%
Basic Earnings Per Share -$0.36
Diluted Earnings Per Share -$362.5K -$342.4K -$19.93K
COMMON SHARES
Basic Shares Outstanding 177.2M 176.6M
Diluted Shares Outstanding 177.3M

Balance Sheet

Concept 2021 Q1 2020 Q4 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $240.4M $300.4M $136.2M
YoY Change 112.6% 120.49% 30.4%
Cash & Equivalents $226.9M $272.1M $114.2M
Short-Term Investments $13.45M $28.24M $22.05M
Other Short-Term Assets $9.900M $7.700M $6.000M
YoY Change 45.59% 28.33% 50.0%
Inventory $5.113M $7.039M $0.00
Prepaid Expenses
Receivables $18.39M $8.646M $22.15M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $273.8M $323.8M $164.3M
YoY Change 118.13% 97.02% 43.72%
LONG-TERM ASSETS
Property, Plant & Equipment $7.035M $7.113M $7.347M
YoY Change -3.23% -3.18% -19.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00
YoY Change -100.0%
Other Assets $3.625M $3.802M $3.590M
YoY Change -4.88% 5.91% 267.08%
Total Long-Term Assets $10.66M $10.92M $10.94M
YoY Change -3.8% -0.2% -66.34%
TOTAL ASSETS
Total Short-Term Assets $273.8M $323.8M $164.3M
Total Long-Term Assets $10.66M $10.92M $10.94M
Total Assets $284.4M $334.7M $175.3M
YoY Change 108.24% 90.96% 19.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.53M $18.71M $13.99M
YoY Change 34.47% 33.78% 80.05%
Accrued Expenses $32.72M $33.94M $21.37M
YoY Change 62.04% 58.87% 34.45%
Deferred Revenue
YoY Change
Short-Term Debt $30.00M $30.00M $29.60M
YoY Change 1.01% 1.35% 1.72%
Long-Term Debt Due $0.00 $9.000M
YoY Change -100.0% 95.65%
Total Short-Term Liabilities $101.2M $105.7M $92.34M
YoY Change 9.17% 14.42% 32.9%
LONG-TERM LIABILITIES
Long-Term Debt $123.0M $119.7M $0.00
YoY Change 237.09% -100.0%
Other Long-Term Liabilities $3.900M $3.900M $3.400M
YoY Change 5.41% 14.71% 25.79%
Total Long-Term Liabilities $123.0M $119.7M $0.00
YoY Change 206.07% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $101.2M $105.7M $92.34M
Total Long-Term Liabilities $123.0M $119.7M $0.00
Total Liabilities $224.2M $225.4M $92.34M
YoY Change 68.73% 144.1% 27.92%
SHAREHOLDERS EQUITY
Retained Earnings -$1.088B -$1.023B -$840.6M
YoY Change 23.85% 21.75% 14.84%
Common Stock $1.777M $1.769M $1.541M
YoY Change 15.24% 14.8% 39.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$74.99M -$19.26M $38.25M
YoY Change
Total Liabilities & Shareholders Equity $284.4M $334.7M $175.3M
YoY Change 108.24% 90.96% 19.37%

Cashflow Statement

Concept 2021 Q1 2020 Q4 2019 Q4
OPERATING ACTIVITIES
Net Income -$64.28M -$60.49M -$2.622M
YoY Change 70.97% 2207.13% -90.44%
Depreciation, Depletion And Amortization $178.0K $180.0K $180.0K
YoY Change -18.35% 0.0% -10.0%
Cash From Operating Activities -$61.01M -$44.64M -$10.44M
YoY Change 162.06% 327.59% -56.48%
INVESTING ACTIVITIES
Capital Expenditures -$100.0K -$150.0K -$80.00K
YoY Change -16.67% 87.5% -27.27%
Acquisitions
YoY Change
Other Investing Activities $14.77M $21.57M $16.34M
YoY Change 36.25% 32.01% -632.25%
Cash From Investing Activities $14.67M $21.41M $16.26M
YoY Change 36.82% 31.67% -612.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $58.50M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $2.900M 198.9M 78.46M
YoY Change 990.23% 153.47% 5799.25%
NET CHANGE
Cash From Operating Activities -$61.01M -44.64M -10.44M
Cash From Investing Activities $14.67M 21.41M 16.26M
Cash From Financing Activities $2.900M 198.9M 78.46M
Net Change In Cash -$43.44M 175.6M 84.28M
YoY Change 253.41% 108.4% -426.29%
FREE CASH FLOW
Cash From Operating Activities -$61.01M -$44.64M -$10.44M
Capital Expenditures -$100.0K -$150.0K -$80.00K
Free Cash Flow -$60.91M -$44.49M -$10.36M
YoY Change 162.99% 329.44% -56.62%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
177182751
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000
CY2018 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-7079000 USD
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
176883000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020 us-gaap Open Tax Year
OpenTaxYear
2017 2018 2019
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2018Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
176883000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
154082000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
154082000
CY2020 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
52420000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
272127000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
114172000 USD
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
2221000 USD
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1551000 USD
CY2019 bcrx Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
11765000
CY2020 bcrx Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
3511000
CY2019 us-gaap Advertising Expense
AdvertisingExpense
0 USD
CY2018 us-gaap Advertising Expense
AdvertisingExpense
0 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2020 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
4080000 USD
CY2019 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
4938000 USD
CY2018 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
4905000 USD
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
1456000 USD
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
281000 USD
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
18000 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
28239000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
22054000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8646000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
22146000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
7039000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
0 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5528000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4422000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
323800000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
164345000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7113000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7347000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3802000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3590000 USD
CY2020Q4 us-gaap Assets
Assets
334715000 USD
CY2019Q4 us-gaap Assets
Assets
175282000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
18713000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13988000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33942000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21365000 USD
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
21670000 USD
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
14904000 USD
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
150000 USD
CY2019Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2120000 USD
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1179000 USD
CY2019Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1377000 USD
CY2020Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
0 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1023442000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-840628000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-19262000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
38252000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
334715000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
175282000 USD
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
17812000 USD
CY2019Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
9020000 USD
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
30000000 USD
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
29561000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
105654000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
92335000 USD
CY2020Q4 bcrx Future Royalties Payable
FutureRoyaltiesPayable
124717000 USD
CY2019Q4 bcrx Future Royalties Payable
FutureRoyaltiesPayable
0 USD
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
3871000 USD
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
3406000 USD
CY2020Q4 us-gaap Line Of Credit
LineOfCredit
0 USD
CY2019Q4 us-gaap Line Of Credit
LineOfCredit
41289000 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
119735000 USD
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1769000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
1541000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1002408000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
877300000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
39000 USD
CY2019 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
48835000 USD
CY2018 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
20653000 USD
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1550000 USD
CY2019 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3726000 USD
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
122964000 USD
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
107068000 USD
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
84888000 USD
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
67929000 USD
CY2019 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
37121000 USD
CY2018 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
29514000 USD
CY2020 us-gaap Royalty Expense
RoyaltyExpense
126000 USD
CY2019 us-gaap Royalty Expense
RoyaltyExpense
375000 USD
CY2018 us-gaap Royalty Expense
RoyaltyExpense
471000 USD
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
192569000 USD
CY2019 us-gaap Costs And Expenses
CostsAndExpenses
148290000 USD
CY2018 us-gaap Costs And Expenses
CostsAndExpenses
114873000 USD
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-174757000 USD
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-99455000 USD
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-94220000 USD
CY2020 bcrx Interest And Other Income Loss
InterestAndOtherIncomeLoss
9420000 USD
CY2019 bcrx Interest And Other Income Loss
InterestAndOtherIncomeLoss
1933000 USD
CY2018 bcrx Interest And Other Income Loss
InterestAndOtherIncomeLoss
2252000 USD
CY2020 us-gaap Interest Expense
InterestExpense
14501000 USD
CY2019 us-gaap Interest Expense
InterestExpense
11892000 USD
CY2018 us-gaap Interest Expense
InterestExpense
9176000 USD
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2011000 USD
CY2020 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-965000 USD
CY2019 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
517000 USD
CY2018 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-108000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-182814000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-108897000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-101252000 USD
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-36000 USD
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
336000 USD
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-54000 USD
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-182850000 USD
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-108561000 USD
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-101306000 USD
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.09
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.94
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.98
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
167267000
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115600000
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
103185000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-182814000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-108897000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-101252000 USD
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
748000 USD
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
724000 USD
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
770000 USD
CY2018 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-7000 USD
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
14794000 USD
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
17719000 USD
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
9396000 USD
CY2020 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2428000 USD
CY2019 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1278000 USD
CY2018 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
885000 USD
CY2020 bcrx Amortization Of Discount And Premium On Investments
AmortizationOfDiscountAndPremiumOnInvestments
121000 USD
CY2019 bcrx Amortization Of Discount And Premium On Investments
AmortizationOfDiscountAndPremiumOnInvestments
117000 USD
CY2018 bcrx Amortization Of Discount And Premium On Investments
AmortizationOfDiscountAndPremiumOnInvestments
110000 USD
CY2020 us-gaap Increase Decrease In Derivative Assets
IncreaseDecreaseInDerivativeAssets
-632000 USD
CY2019 us-gaap Increase Decrease In Derivative Assets
IncreaseDecreaseInDerivativeAssets
-347000 USD
CY2018 us-gaap Increase Decrease In Derivative Assets
IncreaseDecreaseInDerivativeAssets
-1049000 USD
CY2020 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-13903000 USD
CY2019 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
17853000 USD
CY2018 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-1824000 USD
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
7039000 USD
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1649000 USD
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1649000 USD
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2140000 USD
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1364000 USD
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
866000 USD
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
17355000 USD
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
11741000 USD
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4487000 USD
CY2020 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
6766000 USD
CY2019 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
3056000 USD
CY2018 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-247000 USD
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1970000 USD
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1899000 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-137216000 USD
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-89584000 USD
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-92565000 USD
CY2020 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
514000 USD
CY2019 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
343000 USD
CY2018 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
366000 USD
CY2020 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
49818000 USD
CY2019 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
3018000 USD
CY2018 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
62614000 USD
CY2020 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
43475000 USD
CY2019 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
81295000 USD
CY2018 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
67748000 USD
CY2020 bcrx Proceeds From Realized Gain On Investments
ProceedsFromRealizedGainOnInvestments
1000 USD
CY2019 bcrx Proceeds From Realized Gain On Investments
ProceedsFromRealizedGainOnInvestments
0 USD
CY2018 bcrx Proceeds From Realized Gain On Investments
ProceedsFromRealizedGainOnInvestments
0 USD
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6856000 USD
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
77934000 USD
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4768000 USD
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
93279000 USD
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
58500000 USD
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
53400000 USD
CY2020 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
14817000 USD
CY2019 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
19882000 USD
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2446000 USD
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1239000 USD
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2852000 USD
CY2020 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0 USD
CY2019 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
19477000 USD
CY2018 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
10353000 USD
CY2018 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
4025000 USD
CY2020 us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
119867000 USD
CY2020 bcrx Proceeds From Royalty Financing Obligation
ProceedsFromRoyaltyFinancingObligation
124708000 USD
CY2018 bcrx Increase Decrease In Financing Lease Obligations
IncreaseDecreaseInFinancingLeaseObligations
-76000 USD
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
302697000 USD
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
99098000 USD
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
62504000 USD
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
158625000 USD
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
87448000 USD
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-25293000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
115723000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28275000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
53568000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
274348000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
115723000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28275000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
83767000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-101252000 USD
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-54000 USD
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2501000 USD
CY2018 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
351000 USD
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
53400000 USD
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9396000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
49235000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-108897000 USD
CY2019 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
19882000 USD
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17719000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
38252000 USD
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
336000 USD
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
835000 USD
CY2019 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
404000 USD
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
58500000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-182814000 USD
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-36000 USD
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1814000 USD
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
632000 USD
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
93279000 USD
CY2020 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
14817000 USD
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14794000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-19262000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
28211000 USD
CY2020Q4 bcrx Available For Sale Debt Securities Accrued Interest
AvailableForSaleDebtSecuritiesAccruedInterest
25000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
28239000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
326000 USD
CY2020Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
80000 USD
CY2019Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
67000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4896000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3451000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33942000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
21899000 USD
CY2019Q4 bcrx Available For Sale Debt Securities Accrued Interest
AvailableForSaleDebtSecuritiesAccruedInterest
116000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
40000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
22054000 USD
CY2020Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
8243000 USD
CY2019Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
22146000 USD
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
206000 USD
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
2555000 USD
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
4548000 USD
CY2019Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
276000 USD
CY2020Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
270000 USD
CY2019Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
276000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11030000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6190000 USD
CY2020Q4 bcrx Accrued Development Costs
AccruedDevelopmentCosts
15150000 USD
CY2019Q4 bcrx Accrued Development Costs
AccruedDevelopmentCosts
11302000 USD
CY2020Q4 bcrx Accrued Inventory Expense
AccruedInventoryExpense
2453000 USD
CY2019Q4 bcrx Accrued Inventory Expense
AccruedInventoryExpense
29000 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
333000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21365000 USD
CY2020 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
1000 USD
CY2019 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
0 USD
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
17812000 USD
CY2019 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
48835000 USD
CY2018 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
20653000 USD
CY2020 us-gaap Advertising Expense
AdvertisingExpense
6567 USD
CY2020 us-gaap Interest Expense Debt
InterestExpenseDebt
14501000 USD
CY2019 us-gaap Interest Expense Debt
InterestExpenseDebt
11892000 USD
CY2018 us-gaap Interest Expense Debt
InterestExpenseDebt
9176000 USD
CY2020 bcrx Amortization Of Debt Financing Costs And Original Issue Discounts
AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts
1217000 USD
CY2019 bcrx Amortization Of Debt Financing Costs And Original Issue Discounts
AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts
1278000 USD
CY2018 bcrx Amortization Of Debt Financing Costs And Original Issue Discounts
AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts
885000 USD
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.127 pure
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
1754000 USD
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
1464000 USD
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14957
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2805
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2274
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Use of Estimates</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company’s consolidated financial statements relate to the valuation of stock options, </span>the royalty financing <span style="color:#000000;">and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <em style="font: inherit;">not</em> readily apparent from other sources. Actual results could differ from those estimates.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p>
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14449000 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13935000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7336000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6588000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7113000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7347000 USD
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
748000 USD
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
724000 USD
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
770000 USD
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P13Y1M6D
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1302000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
758000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
619000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
577000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
582000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
7327000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
11165000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6115000 USD
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
1696000 USD
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
1457000 USD
CY2020Q4 bcrx Operating Lease Rightofuse Asset Accumulated Amortization
OperatingLeaseRightofuseAssetAccumulatedAmortization
2641000 USD
CY2019Q4 bcrx Operating Lease Rightofuse Asset Accumulated Amortization
OperatingLeaseRightofuseAssetAccumulatedAmortization
1386000 USD
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
10471000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.69
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
4543000
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
4.12
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1596000
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
3.96
CY2017Q4 bcrx Maximum Aggregate Offering Price
MaximumAggregateOfferingPrice
200000000 USD
CY2018Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
10455000
CY2018Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
5.50
CY2018Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
53400000 USD
CY2019Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
43621000
CY2019Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.45
CY2019Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
58500000 USD
CY2019Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
11765000
CY2019Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.69
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
CY2019Q4 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
19882000 USD
CY2020Q2 bcrx Maximum Aggregate Offering Price
MaximumAggregateOfferingPrice
500000000 USD
CY2020Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
22044
CY2020Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
4.50
CY2020Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
108096000000 USD
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14794000 USD
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17719000 USD
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9396000 USD
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14794000 USD
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17719000 USD
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9396000 USD
CY2020 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
18
CY2020Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
29056
CY2020 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y6M
CY2020Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
6.14
CY2020Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
13036
CY2020Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
3.27
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
11688000
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.77
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
16020000
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.25
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
56094000 USD
CY2020Q4 bcrx Employee Service Sharebased Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Next Year
EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear
17758000 USD
CY2020Q4 bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Two
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo
16281000 USD
CY2020Q4 bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Three
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree
12484000 USD
CY2020Q4 bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Four
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour
9571000 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-176613000 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-6201000 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-182814000 USD
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-38391000 USD
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-22868000 USD
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-21263000 USD
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2544000 USD
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1591000 USD
CY2018 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2547000 USD
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
774000 USD
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
691000 USD
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
503000 USD
CY2020 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-82000 USD
CY2019 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
625000 USD
CY2018 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-29000 USD
CY2020 bcrx Income Tax Reconciliation Income Tax Expense Benefit Expiration Of Carry Forwards
IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards
3774000 USD
CY2019 bcrx Income Tax Reconciliation Income Tax Expense Benefit Expiration Of Carry Forwards
IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards
3976000 USD
CY2018 bcrx Income Tax Reconciliation Income Tax Expense Benefit Expiration Of Carry Forwards
IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards
2183000 USD
CY2020 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
542000 USD
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
38551000 USD
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
23824000 USD
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
26040000 USD
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
271734000 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
8230000 USD
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3801000 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
7210000 USD
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5976000 USD
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1020000 USD
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1234000 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
7210000 USD
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
159939000 USD
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
155190000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
66331000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
63275000 USD
CY2020Q4 bcrx Deferred Tax Assets Royalty Income
DeferredTaxAssetsRoyaltyIncome
28034000 USD
CY2019Q4 bcrx Deferred Tax Assets Royalty Income
DeferredTaxAssetsRoyaltyIncome
0 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
10732000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
9786000 USD
CY2020Q4 bcrx Deferred Tax Assets Leasing Obligations
DeferredTaxAssetsLeasingObligations
1135000 USD
CY2019Q4 bcrx Deferred Tax Assets Leasing Obligations
DeferredTaxAssetsLeasingObligations
1070000 USD
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
5563000 USD
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
233122000 USD
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
124000 USD
CY2019Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
114000 USD
CY2020Q4 bcrx Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
854000 USD
CY2019Q4 bcrx Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
803000 USD
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
978000 USD
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
917000 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
270756000 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
232205000 USD
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
38551000 USD
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
23824000 USD
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
26040000 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1569000 USD
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
926000 USD
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
724000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4823000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2871000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6102000 USD
CY2020Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4016000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-37599000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-38607000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-46115000 USD
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-60493000 USD
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.26
CY2020Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2019Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5887000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1448000 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1775000 USD
CY2019Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
39725000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-31054000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-37592000 USD
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-2622000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-37629000 USD
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02

Files In Submission

Name View Source Status
0001171843-21-001411-index-headers.html Edgar Link pending
0001171843-21-001411-index.html Edgar Link pending
0001171843-21-001411.txt Edgar Link pending
0001171843-21-001411-xbrl.zip Edgar Link pending
bcrx-20201231.xsd Edgar Link pending
bcrx-20201231_cal.xml Edgar Link unprocessable
bcrx-20201231_def.xml Edgar Link unprocessable
bcrx-20201231_lab.xml Edgar Link unprocessable
bcrx-20201231_pre.xml Edgar Link unprocessable
bcrx20201231_10k.htm Edgar Link pending
bcrx20201231_10k_htm.xml Edgar Link completed
compound1028.jpg Edgar Link pending
exh1082_01.jpg Edgar Link pending
exh1082_02.jpg Edgar Link pending
exh1082_03.jpg Edgar Link pending
exh1087_01.jpg Edgar Link pending
exh1087_02.jpg Edgar Link pending
exh1087_03.jpg Edgar Link pending
exh1087_04.jpg Edgar Link pending
exh1087_05.jpg Edgar Link pending
ex_227978.htm Edgar Link pending
ex_227979.htm Edgar Link pending
ex_227980.htm Edgar Link pending
ex_227981.htm Edgar Link pending
ex_227982.htm Edgar Link pending
ex_230463.htm Edgar Link pending
ex_230468.htm Edgar Link pending
ex_230469.htm Edgar Link pending
ex_230470.htm Edgar Link pending
ex_230471.htm Edgar Link pending
ex_230489.htm Edgar Link pending
ex_230490.htm Edgar Link pending
ex_230492.htm Edgar Link pending
ex_230493.htm Edgar Link pending
ex_230494.htm Edgar Link pending
ex_230497.htm Edgar Link pending
ex_230510.htm Edgar Link pending
ex_230714.htm Edgar Link pending
ex_230719.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
footer1026.jpg Edgar Link pending
header1026.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending